Q-omics provides the consensus-scored AK3P5 profile across patient tissues and cancer cell-line models. AK3P5 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, AK3P5 is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, AK3P5 RNA expression shows 13,767 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, STAD, and UVM as cancer lineages where AK3P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AK3P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AK3P5 survival associations across molecular data types. AK3P5 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AK3P5 RNA expression–survival associations across cancer types. High AK3P5 expression shows unfavorable associations in LUSC, KIRP, UVM and UCEC, but favorable associations in BRCA and SKCM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for AK3P5 RNA expression.
This table summarizes AK3P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for AK3P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AK3P5 shows lower tumor expression in BRCA and THCA and higher tumor expression in STAD, LIHC, CHOL and COAD. The STAD box plot shows higher AK3P5 RNA expression in tumor versus normal tissue (log2 FC = +0.371, t-test p = .007).
This table shows molecular features associated with AK3P5 in patient tissues and cancer cell lines. In patient samples, AK3P5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
